Boryung Pharmaceutical Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Boryung Pharmaceutical Co., Ltd.
Korea Q1 Roundup: Mixed Earnings Amid M&A, Prescription Sales
Large Korean pharma firms’ first-quarter earnings were mostly mixed on a range of diverse factors such as solid prescription sales and impacts from acquisitions, with some even looking to space for new business opportunities.
Korea Q4 Roundup: International Growth A Key Factor For Major Firms
Aside from record earnings reported by a number of Korean pharma companies, the industry saw a diverse range of headlines in the fourth quarter, including cross-border acquisitions and business diversification.
Deal Watch: Sol-Gel To Tackle Gorlin Syndrome In Pact With BridgeBio’s PellePharm
Shoreline picks up technology platform rights and access from Editas, which recently reduced staff. Hyloris out-licenses commercial rights to Maxigesic in nine EU markets to Salus.
Lunsumio Provides First Test For Korea's Breakthrough Therapy Program
South Korea's breakthrough therapy system, Global Innovative Products Fast Track, kicks off with Roche’s follicular lymphoma drug becoming the first to test the new system. Meanwhile, a state-run group is linking with pharma firms to rapidly bring in global new drugs.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.